Search and analyze individual stocks with comprehensive metrics
NOVELIX PHARMACEUTICALS LIMITE
Fundamental Score
NOVELIX PHARMACEUTICALS LIMITE Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of NOVELIX across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Robust Profit Growth (307.69%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Strong Revenue Growth (818.18%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.
Consistent Growth Track Record (82.92% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Balanced Promoter Holding (54.82%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
12 factors identified
Below-Average Return on Equity (0.64%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (0.96%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.
Margin Pressure Concerns (-12.77%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges. Monitor for operational improvements.
Premium Valuation Risk (P/E: 104.85x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.
Weak Earnings Growth (-6.26% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.
Stagnant Profit Growth (-2.33% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity. Assess transformation initiatives.
Negative Free Cash Flow (₹-17.48 Cr over 5Y)
Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.
Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Very Low ROE
Observation: Poor capital utilization and shareholder returns.
Analysis: ROE below 5% suggests significant inefficiencies in capital deployment.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Very High P/E Ratio
Observation: Significant overvaluation risk present.
Analysis: Extremely high P/E ratios indicate potential bubble territory and high downside risk.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
Loading Peer Comparison
Finding companies in the Healthcare Research, Analytics & Technology sector...
Financial Statements
Comprehensive financial data for NOVELIX PHARMACEUTICALS LIMITE
About NOVELIX
Business Overview
Novelix Pharmaceuticals Limited trades in pharmaceuticals and related products in India. It also trades in shares and securities; retails pharmaceuticals; and offers marketing services. The company was formerly known as Trimurthi Limited and changed its name to Novelix Pharmaceuticals Limited in October 2024. Novelix Pharmaceuticals Limited was incorporated in 1994 and is based in Hyderabad, India.
Company Details
Key Leadership
Corporate Events
Latest News
NOVELIX Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of NOVELIX PHARMACEUTICALS LIMITE (NOVELIX)?
As of 20 Jan 2026, 11:04 am IST, NOVELIX PHARMACEUTICALS LIMITE (NOVELIX) is currently trading at ₹54.00. The stock has a market capitalization of ₹101.70 (Cr).
Is NOVELIX share price Overvalued or Undervalued?
NOVELIX is currently trading at a P/E ratio of 104.85x, compared to the industry average of 45.95x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.
What factors affect the NOVELIX PHARMACEUTICALS LIMITE share price?
Key factors influencing NOVELIX's price include its quarterly earnings growth (Sales Growth: 818.18%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is NOVELIX PHARMACEUTICALS LIMITE a good stock for long-term investment?
NOVELIX PHARMACEUTICALS LIMITE shows a 5-year Profit Growth of -2.33% and an ROE of 0.64%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing.
How does NOVELIX PHARMACEUTICALS LIMITE compare with its industry peers?
NOVELIX PHARMACEUTICALS LIMITE competes with major peers in the Healthcare Research, Analytics & Technology. Investors should compare NOVELIX's P/E of 104.85x and ROE of 0.64% against the industry averages to determine its competitive standing.
What is the P/E ratio of NOVELIX and what does it mean?
NOVELIX has a P/E ratio of 104.85x compared to the industry average of 45.95x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹105 for every ₹1 of annual earnings.
How is NOVELIX performing according to Bull Run's analysis?
NOVELIX has a Bull Run fundamental score of 40.6/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does NOVELIX belong to?
NOVELIX operates in the Healthcare Research, Analytics & Technology industry. This classification helps understand the competitive landscape and sector-specific trends affecting NOVELIX PHARMACEUTICALS LIMITE.
What is Return on Equity (ROE) and why is it important for NOVELIX?
NOVELIX has an ROE of 0.64%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently NOVELIX PHARMACEUTICALS LIMITE generates profits from shareholders' equity.
How is NOVELIX's debt-to-equity ratio and what does it indicate?
NOVELIX has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is NOVELIX's dividend yield and is it a good dividend stock?
NOVELIX offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has NOVELIX grown over the past 5 years?
NOVELIX has achieved 5-year growth rates of: Sales Growth 82.92%, Profit Growth -2.33%, and EPS Growth -6.26%.
What is the promoter holding in NOVELIX and why does it matter?
Promoters hold 54.82% of NOVELIX shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is NOVELIX's market capitalization category?
NOVELIX has a market capitalization of ₹102 crores, placing it in the Small-cap category.
How volatile is NOVELIX stock?
NOVELIX has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for NOVELIX?
NOVELIX has a 52-week high of ₹N/A and low of ₹N/A.
What is NOVELIX's operating profit margin trend?
NOVELIX has a 5-year average Operating Profit Margin (OPM) of -12.77%, indicating the company's operational efficiency.
How is NOVELIX's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 818.18% and YoY Profit Growth of 307.69%.
What is the institutional holding pattern in NOVELIX?
NOVELIX has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the stock.